Fairtility expands CHLOE AI platform across First Fertility network
Fairtility has announced an expanded partnership with First Fertility, one of the larger fertility clinic networks in the United States, to deploy its CHLOE platform across multiple laboratories following a successful single-site pilot. The Tel Aviv-based company says CHLOE is now being rolled out to all existing timelapse-equipped centres within the First Fertility network, with further deployments planned as additional sites adopt timelapse technology.
The initial deployment at one First Fertility centre was assessed on both clinical workflow integration and patient-facing engagement. The network's chief scientific officer, Dr Alison Bartolucci, said patients responded positively to greater visibility into embryo development, and that expanding to additional sites was "a natural next step" following that experience.
What CHLOE does
CHLOE is a software layer built on timelapse imaging hardware. It combines AI-assisted embryo and egg quality assessment with patient communication tools, aiming to reduce the information gap between laboratory processes and patient understanding during the IVF cycle. Fairtility positions the platform as covering clinical decision support, operational workflow, and patient engagement within a single interface.
Eran Eshed, chief executive and co-founder of Fairtility, said the future of IVF involves giving patients greater transparency throughout treatment, framing the First Fertility expansion as evidence of that direction gaining commercial traction. Fairtility says CHLOE is now deployed in more than 100 fertility clinics across North America, Europe, Asia-Pacific, and Latin America.
No financial terms for the expanded partnership were disclosed, and Fairtility did not provide throughput figures, embryo-assessment accuracy benchmarks, or comparative clinical outcome data in its release.
Market context
AI-assisted embryo selection is a competitive and increasingly scrutinised segment. A number of companies, including iDAScore from Vitrolife and other computer-vision-based embryo grading tools, are pursuing similar approaches to automated assessment within fertility clinics. Buyers in the sector, typically IVF clinic groups and larger fertility networks, evaluate these platforms on regulatory clearance status, integration with timelapse hardware vendors, and evidence from peer-reviewed clinical studies.
Regulatory oversight of AI-assisted reproductive technology tools is tightening across key markets. In the United States, the FDA classifies software that claims to influence embryo selection as a medical device, meaning vendors must navigate 510(k) clearance or De Novo pathways for certain capabilities. In the EU, the AI Act places high-risk classification on AI systems used in medical diagnosis, which will affect software of this type as obligations phase in from 2026 onwards. Fairtility's release does not address regulatory status in any of its markets, which editors may wish to clarify before publication.
The patient-engagement framing in Fairtility's release reflects a broader commercial trend in fertility technology, where clinic groups are differentiating on experience and transparency as much as on clinical outcomes. For enterprise software buyers evaluating platforms in this space, clarity on regulatory clearance, outcome data, and hardware interoperability will remain the primary due-diligence questions.